



Please download and read the instructions before proceeding to the peer review

### Pirfenidone for the treatment of idiopathic pulmonary fibrosis

Journal:	<i>Expert Opinion On Pharmacotherapy</i>
Manuscript ID:	EOOP-2013-0267.R1
Manuscript Type:	Drug Evaluation
Keywords:	Antifibrotic drugs, Idiopathic pulmonary fibrosis, Pirfenidone, Treatment

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**PIRFENIDONE FOR THE TREATMENT OF IDIOPATHIC  
PULMONARY FIBROSIS**

For Peer Review Only

**ABSTRACT**

**Introduction.** Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and lethal fibrosing interstitial pneumonia. The median survival from the onset of the symptoms is 2.8-4.2 years and the 5-year survival rate is 20%. Its poor prognosis, combined with the scarcity of treatment options, provides a strong rationale for the development of novel therapeutic strategies. During the last decade there has been a huge rise in clinical trials with antifibrotic drugs, although only pirfenidone has shown a beneficial effect.

**Areas covered.** This article reviews the medical literature on the effectiveness and safety of pirfenidone in IPF, by means of a PubMed search from 1995 to present, completed by some data on file from the manufacturer.

**Expert opinion.** Pirfenidone is the only antifibrotic drug approved for the treatment of IPF. Pirfenidone presents a meaningful clinical effect on reductions in the decrease in forced vital capacity (FVC), six minute walk test (6MWT) distance and mortality, and it improves the progression-free survival in IPF patients with mild-moderate disease. Pirfenidone is well tolerated, with the most common side-effects being gastrointestinal discomfort and photosensitivity. Pirfenidone has a favorable benefit-risk profile and represents a suitable treatment option for patients with mild-moderate IPF.

**Key words.** Antifibrotic drugs, Idiopathic Pulmonary Fibrosis, Pirfenidone

## 1. INTRODUCTION

IPF is a chronic, progressive, and lethal fibrosing interstitial pneumonia, limited to the lung and associated with the histopathological and/or radiological pattern of usual interstitial pneumonia (1). Although its etiology is unknown and the pathogenesis only partly understood, our current knowledge suggests that damage to the alveolar epithelium is probably an important early event followed by an aberrant healing response. The median age at diagnosis is 66 years, with a male predominance, and prevalence has been increasing in recent years. The incidence of IPF is estimated to be between 4.6 and 7.4 cases / 100000, and the prevalence is between 13 cases/100000 for females and 20 cases/100000 for males (1). IPF is characterized by a progressive decline in pulmonary function, which quickly leads to respiratory failure and death, although some patients may have episodes of acute respiratory worsening despite previous stability. With a median survival from the onset of the symptoms of 2.8-4.2 years and a 5-year survival rate approaching 20%, IPF is more lethal than many malignant diseases. The poor prognosis, combined with the scarcity of treatment options, provides a strong rationale for the development of novel therapeutic strategies for this disease. During the last decade there has been a huge rise in clinical trials with antifibrotic drugs. In phase III randomized clinical trials with interferon gamma 1-b, pirfenidone, macitentan, bosentan, ambrisentan, warfarin, triple therapy (n-acetylcysteine, glucocorticoids, azathioprine), etanercept and sildenafil, only pirfenidone has shown any beneficial effects in patients with IPF (2-4). Several national guidelines on IPF diagnosis and treatment from Spain, Germany, Denmark, Sweden, Austria, and Ireland, have recently recommended pirfenidone as first-choice therapeutic

1  
2  
3 agent in IPF patients with mild-moderate disease, defined as FVC predicted >  
4  
5 50% (5-9). The National Institute for Health and Clinical Excellence (NICE)  
6  
7 recommends pirfenidone as a therapeutic option in IPF patients with FVC  
8  
9 predicted between 50 and 80%. (10).  
10

## 11 12 13 14 **2. OVERVIEW OF THE MARKET**

15  
16 Pirfenidone is the only pharmacological agent approved for the treatment of  
17  
18 mild-moderate IPF (11). Nowadays, there is no drug available for the treatment  
19  
20 of patients with IPF with advanced disease.  
21

## 22 23 24 25 **3. INTRODUCTION TO PIRFENIDONE**

26  
27 Pirfenidone is a pleiotropic molecule with antifibrotic, anti-inflammatory and  
28  
29 antioxidant effects (12). The antioxidant effect occurs through its ability to  
30  
31 scavenge reactive oxygen species (13). Studies in animal models of pulmonary  
32  
33 fibrosis have shown that pirfenidone attenuates a range of inflammatory and  
34  
35 profibrotic molecules while downregulating histological markers of fibrosis and  
36  
37 cellular proliferation (14). Pirfenidone inhibits the expression of transforming  
38  
39 growth factor (TGF)- $\beta$  and the tissue inhibitor of metalloproteinase-1 (TIMP-1),  
40  
41 and blocks the proliferative effects of platelet-derived growth factor (PDGF).  
42  
43 Furthermore, pirfenidone inhibits the release of proinflammatory cytokines such  
44  
45 as, tumor necrosis factor (TNF)- $\alpha$ , interleukin (IL-1)- $\beta$ , IL-6, IL-8 and IL-12, as  
46  
47 well increasing the expression of the anti-inflammatory cytokine IL-10,  
48  
49 attenuating the release of chemotactic cytokines and reducing the accumulation  
50  
51 of inflammatory cells in response to different stimuli (14-19)  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In addition to the modulation of mediators in animal models, cell-based assays  
4 have demonstrated that pirfenidone inhibits the expression of heat shock  
5 protein (HSP) 47 in cultured normal lung fibroblasts stimulated with TGF- $\beta$ -1; it  
6 was also able to inhibit the expression of collagen in fibroblasts isolated from  
7 IPF patients (20, 21). Moreover, pirfenidone inhibits the overexpression of  
8 collagen type I and HSP47 in the alveolar epithelial cell line (A549 cells), (22).  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

### 19 **3.1 CHEMISTRY**

20 Pirfenidone is an orally bioavailable synthetic molecule. Pirfenidone is a  
21 heterocyclic pyridine (5-methyl-1-phenyl-2-[1H]-pyridine) with a molecular  
22 weight of 185.22. Pyridines are derived from coal combustion, and can be  
23 synthesized from aldehyde and ammonia. They are highly soluble in  
24 dimethylsulfoxide, twice in water and chloroform, and in alcohol. In aqueous  
25 solution the maximum possible concentration is 2%. (23).  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

### 36 **3.2 PHARMACOKINETICS AND METABOLISM**

37 Oral pirfenidone has linear pharmacokinetics over the dose range of 200-600  
38 mg. (24). After a single dose of pirfenidone with food at the recommended  
39 maintenance dose of 801 mg, the mean maximum plasma concentration ( $C_{max}$ )  
40 is 7.9 mg/L in healthy adults. Absorption occurs quickly, the time to maximum  
41 ( $T_{max}$ ) values being achieved in 30-60 min (25). Median time to  $C_{max}$  is 3.5 h.  
42 However, the  $C_{max}$  is significantly lower when the drug is administered in the fed  
43 versus fasting states (26). It has been shown that healthy volunteers who  
44 received pirfenidone with food had a lower incidence of gastrointestinal adverse  
45 events, than those who received pirfenidone without food. In clinical trials, at  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 concentrations of 1-1000 mg/L, 50-58% of pirfenidone bound to plasma  
4  
5 proteins, predominantly albumin (27). Pirfenidone is predominantly metabolized  
6  
7 by the cytochrome (CYP) P450 CYP1A2 enzyme, although other CYP  
8  
9 enzymes, including CYP2C9, 2C19, 2D6, and 2E, also contribute to the  
10  
11 metabolism. The major metabolite of pirfenidone is 5-carboxy-pirfenidone which  
12  
13 is inactive. After a single 801 mg dose, the terminal elimination half life was 2.9  
14  
15 h (without food) and 2.4 h (with food). No significant gender differences were  
16  
17 noted for the pharmacokinetic variables (26). Eighty percent of the administered  
18  
19 dose was excreted in the urine primarily as 5-carboxy-pirfenidone and less than  
20  
21 1% of the dose recovered in the urine was unaltered, after 6 h of administration.  
22  
23 Pirfenidone bioavailability is increased by a mean of 60% in patients with  
24  
25 moderate hepatic function impairment. No clinical relevant changes have been  
26  
27 observed in pharmacokinetics in patients with mild to severe renal function  
28  
29 impairment. However, the drug is contraindicated in patients with severe renal  
30  
31 impairment (creatinine clearance of < 30 mL/min) or end stage renal disease  
32  
33 requiring dialysis. (28)

34  
35  
36  
37  
38 Pirfenidone may interact with drugs that inhibit CYP1A2, particularly  
39  
40 fluvoxamine, ciprofloxacin, and propafenone. Consumption of grapefruit also  
41  
42 inhibits CYP1A2. Concomitant treatment with inhibitors of other CYP  
43  
44 isoenzymes involved in the metabolism of pirfenidone (fluconazole,  
45  
46 chloramfenicol, fluoxetine, paroxetine, amiodarone) may interact with  
47  
48 pirfenidone. Pirfenidone can also interact with CYP1A2, inducers, such as  
49  
50 tobacco smoke and omeprazole (27) (Table 1).  
51  
52  
53  
54

#### 55 56 **4. CLINICAL EFFICACY** 57 58 59 60

#### 4.1 Clinical trials

In a prospective, open-label phase II study, pirfenidone was evaluated for its tolerability and usefulness in patients with advanced IPF, progressive disease and lack of response to conventional therapy (prednisone with or without immunosuppressives). Fifty-four patients were followed for mortality, changes in lung function and adverse effects. Patients whose lung function had deteriorate before enrolment appeared to stabilize after beginning treatment. Patients with higher single-breath diffusing capacity for carbon monoxide ( $DL_{CO}$ ) (> 30% predicted) at entry had longer survival. The adverse effects were minor (29).

The first large-scale trial of pirfenidone was a Japanese multicenter randomized placebo-controlled phase II study of 107 subjects who received either pirfenidone 600 mg three times daily (n = 72) or placebo (n = 35). The trial was designed to run for 1 year. Although there was a significant decrease in the decline of FVC in the pirfenidone group, 9-month interim results showed that five subjects from the placebo group had suffered acute exacerbation of the disease compared to none in the pirfenidone group, and the study was halted (30).

A phase III clinical trial conducted over 52 weeks was also developed in Japan. A total of 275 patients were randomized to either high-dose (1800 mg/day) or low-dose (1200 mg/day) pirfenidone or placebo the ratio of 2:1:2. Significant differences were observed in vital capacity (VC) decline (primary end-point) between the placebo group and the high-dose group and improved progression-free survival time was seen in the high-dose group. (31). To find out which patients specifically benefit from pirfenidone, an additional exploratory analysis was performed with the data of this trial. Significant efficacy of pirfenidone in



1  
2  
3 reducing the decline in VC was seen in a subpopulation with %VC  $\geq$  70% and  
4  
5 oxygen saturation at baseline (SpO<sub>2</sub>) < 90%. These are mutually conflicting  
6  
7 characteristics. According to the author opinion, the desaturation exhibited by  
8  
9 the subgroup with the better-preserved lung function may have been due to the  
10  
11 development of fibrosis with inflammatory edema and not to established fibrosis.  
12  
13 In this subpopulation, pirfenidone also suppressed cough and dyspnea (32).  
14  
15 Recently, marginal decline in FVC (5%) has been reported as being associated  
16  
17 with poor outcome in IPF. In the same clinical trial, Taniguchi et al sought to  
18  
19 evaluate the efficacy of pirfenidone from the aspects of 5% changes in VC.  
20  
21 When 5% change in VC was used as an index instead of the 10% change, the  
22  
23 efficacy of pirfenidone could be evaluated with higher sensitivity over the 12  
24  
25 months study. (33).  
26  
27

28  
29 The CAPACITY phase III trials consisted of two concurrent multinational  
30  
31 randomized double-blind placebo-controlled phase III trials (004 and 006)  
32  
33 conducted over 72 weeks and designed to evaluate the safety and efficacy of  
34  
35 pirfenidone in patients with mild-moderate disease (34, 35). In trial 004, 174  
36  
37 patients were assigned to high-dose pirfenidone (2403 mg/day), 87 to low dose  
38  
39 (1197 mg/day) and 174 to placebo. In study 006, 171 patients were assigned to  
40  
41 high-dose pirfenidone (2403 mg/day), and 173 to placebo. In study 004, the  
42  
43 higher dose of pirfenidone met the primary endpoint, decreasing the decline in  
44  
45 FVC. In contrast, trial 006 failed to show a significant reduction in FVC, although  
46  
47 there was a reduced decline in distance walked in the 6MWT (secondary end-  
48  
49 point). The differences observed between the two studies in the effect of  
50  
51 pirfenidone may be explained by the fact that the subjects in the 006 placebo  
52  
53 group had a slower rate of decline compared to those in 004. When 004 and  
54  
55  
56  
57  
58  
59  
60

006 study data were pooled, pirfenidone shows meaningful clinical effects on FVC % predicted (decrease in the decline by 30%), progression free survival and 6MWT distance at the dose of 2403 mg/day.. Although these trials were not powered to detect an effect on mortality, IPF-related mortality was reduced by 28%. A Cochrane review encompassing the two Japanese trials and the CAPACITY studies, has demonstrated that pirfenidone improves progression-free survival by 30%. (36).

The RECAP study is an ongoing open-label extension study evaluating the long-term administration of pirfenidone in patients who completed phase III CAPACITY program. Preliminary results in 178 patients show that FVC and survival outcomes in patients newly treated with pirfenidone in the RECAP study were similar to those treated in the CAPACITY trials. These data provide further evidence to support the beneficial effect of pirfenidone in IPF (37). A phase III study comparing pirfenidone with placebo in patients with mild-to-moderate IPF is currently under way in the US (ASCEND trial, NCT01366299). The PANORAMA study (A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Safety and Tolerability of *N*-Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone, EUDRACT 2012-000564-14) is also ongoing.

#### 4.2 Posology and method of administration

Pirfenidone is indicated in adults for the treatment of mild-to-moderate IPF (FVC > 50% predicted (5-9). The National Institute for Health and Clinical Excellence recommends pirfenidone in patients with FVC between 50% and 80% predicted (10). The approved dose is 2403 mg/day. Each capsule contains 267 mg. Upon

1  
2  
3 initiating treatment, the dose should be titrated to the recommended daily dose  
4  
5 over a 14-day period: days 1 to 7, one capsule three times a day (801 mg/day);  
6  
7 days 8 to 14, two capsules, three times a day (1602 mg/day) and day 15  
8  
9 onward, three capsules, three times a day (2403 mg/day). The drug should be  
10  
11 taken with food to reduce the possibility of gastrointestinal adverse events and  
12  
13 dizziness (27). The recommended treatment duration is at least 12 months. If  
14  
15 there is improvement or stabilization of the disease, the treatment should be  
16  
17 continued. In case of deterioration, the advisability of continuing treatment or  
18  
19 instigating other therapeutic strategies should be considered for each patient.  
20  
21 However, it is recommended that treatment should be discontinued if there is  
22  
23 evidence of disease progression, that is, a decline in per cent predicted FVC of  
24  
25 10% or more within any 12 month period (5, 10).  
26  
27  
28  
29  
30  
31

### 32 **4.3 Post marketing studies**

33  
34 Open-label studies have been developed, to confirm the efficacy, safety and  
35  
36 tolerability of pirfenidone and to optimize its indications.  
37

38  
39 A European Named Patient Program (NPP) was established by Intermune® to  
40  
41 make pirfenidone accessible to patients with IPF during the period between the  
42  
43 authorization of the drug and its availability upon prescription. The results of this  
44  
45 program have not yet been published. The PASSPORT study (Post-  
46  
47 Authorisation Safety Study of Esbriet® (Pirfenidone): A Prospective  
48  
49 Observational Registry to Evaluate Long-Term Safety in a Real-World Setting)  
50  
51 is also ongoing; its objective is to evaluate the long-term safety of pirfenidone.  
52

53  
54 In a retrospective study, Okuda et al (38) have described the effects of  
55  
56 pirfenidone, at the dose of 1800 mg/day during 6 months, in 76 patients with  
57  
58  
59  
60

1  
2  
3 mild-to-severe IPF. Pirfenidone tended to attenuate the degree of decline in  
4  
5 FVC, particularly in the subgroup of patients with FVC < 60% and showed  
6  
7 greater efficacy in patients with decline in FVC > 150 ml during the 6-months  
8  
9 period before the start of therapy. Thus, the degree of disease progression prior  
10  
11 to the initiation of therapy had an impact on the response to pirfenidone. The  
12  
13 most frequent adverse effects were anorexia (42%), increase in gamma  
14  
15 glutamyl transpeptidase (22%), fatigue (14%) and photosensitivity (18%). All the  
16  
17 reported adverse effects were, however, mild, reversible and left no sequelae.  
18  
19 Moreover, Bonella et al. (39), have reported data on the safety and efficacy of  
20  
21 pirfenidone (2403 mg/ day) in 45 patients with mild-moderate IPF (mean  
22  
23 duration of treatment 48 weeks). Sixteen patients (35%) received pirfenidone as  
24  
25 monotherapy and 29 (65%) in combination with corticosteroids and /or N-  
26  
27 acetylcysteine. The course of the disease was stable during treatment with  
28  
29 pirfenidone in two out of every three patients. Twenty-six patients (58%)  
30  
31 suffered from side effects, mostly gastrointestinal, but pirfenidone was  
32  
33 discontinued because of side effects in only six patients. The results of this  
34  
35 study confirm the efficacy and safety of pirfenidone in the treatment of IPF.  
36  
37  
38  
39

40 Iwasawa et al. (40) investigated the usefulness of high resolution CT scan  
41  
42 (HRCT) in the imaging assessment of the response to pirfenidone therapy.  
43  
44 Seventy-eight patients (38 treated with pirfenidone and 40 matched controls)  
45  
46 were given HRCT on two occasions, with a one-year interval in between. A  
47  
48 significantly larger proportion of patients treated with pirfenidone showed more  
49  
50 stable pulmonary function parameters than the controls (65.6% vs 37.5%). The  
51  
52 decline in VC correlated with the increase in fibrotic lesions in CT scan. These  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 results suggest that CT scan may be useful for evaluating the pirfenidone-  
4  
5 induced slowing progression of pulmonary fibrosis.  
6  
7

## 9 10 **5. SAFETY AND TOLERABILITY**

11 Jiang et al (41) have reported the results of a meta-analysis to analyze the  
12 safety profile of pirfenidone for treating pulmonary fibrosis. Six-randomized  
13 controlled trials were analyzed. A total of 1073 patients were enrolled, 561 in  
14 the pirfenidone group, and 512 in the placebo group. Four trials assessed the  
15 treatment of IPF and the remaining two studies, assessed the treatment of  
16 Hermansky–Pudlak syndrome (30, 31, 34, 42, 43). The combined results of the  
17 six trials revealed that the pirfenidone group had a significantly higher rate of  
18 gastrointestinal, neurological and dermatological adverse events. However,  
19 adverse effects were generally mild or moderate in severity and without any  
20 clinically significant consequences. Most of the adverse effects disappeared  
21 with a decrease in the dose or temporary discontinuation of medication.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 The most commonly reported ( $\geq 10\%$ ) adverse reactions during treatment with  
37 pirfenidone at a dose of 2403 mg/ day are nausea, rash, fatigue, diarrhea,  
38 dyspepsia and photosensitivity reaction (table 2). Less frequent adverse effects  
39 are anorexia, insomnia, hot flush and alteration in the hepatic enzymes alanin  
40 and aspartate aminotransferases, and gamma glutamyl transferase. (27).  
41  
42  
43  
44  
45  
46  
47

48 Gastrointestinal events are less frequent if the drug is administered with food.  
49 Patients with photosensitivity reaction or rash should use protective sun  
50 creams, to wear clothing that protects against sun exposure and avoid direct  
51 sunlight. In case of adverse events, the dose of pirfenidone should be adjusted  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 or the treatment discontinued, according to the established recommendations.

4  
5 There are no data on the use of pirfenidone during pregnancy. (27).

6  
7 Pirfenidone is contraindicated in case of hypersensitivity to the drug or to any of  
8  
9 its excipients, concomitant use of fluvoxamine, severe hepatic impairment or  
10  
11 end-stage liver disease or severe renal impairment or end-stage renal disease  
12  
13 requiring dialysis. Pirfenidone should be used with caution in patients treated  
14  
15 with inhibitors or inducers of CYP1A2 (table 1) (27).  
16  
17  
18  
19

## 20 21 **6. REGULATORY AFFAIRS**

22  
23 Pirfenidone is an orally administered pyridine that was granted orphan drug  
24  
25 approval in the European Union for the treatment of mild-to-moderate IPF in  
26  
27 2011 and it is the only pharmacological agent available for this indication (44).

28  
29 In Europe, it is marketed under the brand name Esbriet<sup>®</sup> by Intermune Inc. In  
30  
31 Japan, pirfenidone has been approved for marketing since 2008 under the  
32  
33 brand name Pirespa<sup>®</sup> by Shionogi & Co. In 2010, the Food and Drug  
34  
35 Administration (FDA) denied approval for pirfenidone. A new drug application to  
36  
37 the FDA is expected depending on the results of the ongoing phase III trial  
38  
39 ASCEND (Efficacy and safety of Pirfenidone in Patients with Idiopathic  
40  
41 Pulmonary Fibrosis).  
42  
43  
44  
45  
46

## 47 48 **7. CONCLUSION**


49  
50 IPF is a chronic, progressive, and lethal fibrosing interstitial pneumonia. Its poor  
51  
52 prognosis, combined with the scarcity of treatment options, provides a strong  
53  
54 rationale for the development of novel therapeutic strategies for this disease.  
55  
56 During the last decade several clinical trials with antifibrotic drugs have been  
57  
58  
59  
60

1  
2  
3 developed, although only pirfenidone has shown a beneficial effect. Recent  
4 national guidelines and the National Institute for Health and Clinical Excellence  
5 recommend pirfenidone as first-choice therapeutic agent in IPF patients with  
6 mild-moderate disease, defined as FVC > 50% of predicted. Pirfenidone's  
7 adverse-effect profile is acceptable in a disease as severe as IPF. Nowadays,  
8 pirfenidone is the only pharmacological agent approved for the treatment of  
9 mild-moderate IPF.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

## 20 21 **8. EXPERT OPINION**

22 IPF is a progressively fibrotic disease with a median survival from the onset of  
23 the symptoms of 2.8 to 4.2 years. The search for effective treatment has  
24 involved numerous clinical trials with potentially antifibrotic drugs, although only  
25 pirfenidone has shown any beneficial effect. Four key clinical trials have  
26 endorsed the efficacy and tolerability of pirfenidone. Pirfenidone has shown  
27 clinically meaningful effects on decreases in the decline of % FVC, 6MWT  
28 distance and mortality, as well as on improvements in progression-free survival.  
29 In addition, pirfenidone could prevent symptoms related to disease progression,  
30 decrease dependency on oxygen, increase survival and reduce hospitalizations.  
31 Pirfenidone is well tolerated, with the most common side-effects being  
32 gastrointestinal discomfort and photosensitivity. Open-label and placebo-  
33 controlled studies are underway to confirm the efficacy and long-term effects of  
34 pirfenidone. Recently published national guidelines recommend pirfenidone as  
35 a first-choice therapeutic agent in IPF patients with mild-moderate disease.  
36 Pirfenidone has a favorable benefit-risk profile and represents a suitable  
37 treatment option for IPF.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**9. DRUG SUMMARY BOX**

Drug name	Pirfenidone
Phase	Marketed
Indication	mild-moderate idiopathic pulmonary fibrosis
Pharmacology description	antifibrotic, anti-inflammatory, antioxidant
Route of administration	oral
Chemical structure	
Pivotal trials	(30, 31, 34)



**REFERENCES**

1. Raghu G, Collard HR, Egan JJ et al. An official ATS/ERS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med* 2011; 183: 788-824
2. Luppi F, Spagnolo P, Cerri S et al. The big clinical trials in idiopathic pulmonary fibrosis. *Curr Opin Pulm Med* 2012; 18: 428-432
3. Raghu G, Behr J, Brown KK et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel randomised trial. *Ann Intern Med* 2013; 158: 641-649
4. Raghu G, Million-Rousseau R, Morganti A et al. Macitentan for the treatment of IPF: the randomized controlled MUSIC trial. *Eur Respir J* 2013; May 16 (Epub ahead of print)
5. Xaubet A, Ancochea J, Bollo E et al. Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. *Arch Bronconeumol* 2013; 49: 343-353
6. Behr J, Günther A, Ammenwerth W et al. German Guideline for Diagnosis and Management of idiopathic Pulmonary Fibrosis. *Pneumologie* 2013; 67:81-111

- 1  
2  
3  
4  
5 7. Idiopathic pulmonary fibrosis guidelines. Danish Society of Respiratory  
6  
7 Medicine [www.lungemedicin.dk](http://www.lungemedicin.dk) (Last accessed 29 August 2013).  
8  
9  
10  
11  
12 8. Position Statement from the Irish Thoracic Society on the treatment of  
13  
14 idiopathic pulmonary fibrosis  
15  
16 [http://www.irishthoracicsociety.com/images/uploads/ITS%20Statement%](http://www.irishthoracicsociety.com/images/uploads/ITS%20Statement%20Final.pdf)  
17  
18 [20Final.pdf](http://www.irishthoracicsociety.com/images/uploads/ITS%20Statement%20Final.pdf) (Last accessed 28 August 2013).  
19  
20  
21  
22  
23 9. Care programs for idiopathic pulmonary fibrosis .Swedish Society for  
24  
25 Pulmonary Medicine.  
26  
27 [http://www.slmf.se/sites/default/files/VPIL\\_](http://www.slmf.se/sites/default/files/VPIL_) (Last accessed 28 August  
28  
29 [2013](http://www.slmf.se/sites/default/files/VPIL_)  
30  
31  
32  
33  
34 10. Pirfenidone for treating idiopathic pulmonary fibrosis. National Institute for  
35  
36 Health and Clinical Excellence.  
37  
38 <http://guidance.nice.org.uk/TA/Wave23/25/FAD/FinalAppraisalDetermination/pdf/English>. (Last accessed 28 August 2013).  
39  
40  
41  
42  
43  
44  
45 11. Potts J, Yogaratnam D. Pirfenidone: a novel agent for the treatment of  
46  
47 idiopathic pulmonary fibrosis. *Ann Pharmacother* 2013; 47: 361-367  
48  
49 \* A practical and concise recent review on pirfenidone  
50  
51  
52  
53  
54 12. Schaefer CJ, Ruhmund DW, Pan L et al. Antifibrotic activities of pirfenidone  
55  
56 in animal models. *Eur Respir Rev* 2011;20:120,85-97  
57  
58  
59  
60

1  
2  
3 \* Updated review on the antifibrotic effects of pirfenidone in animal models of  
4  
5 pulmonary fibrosis.  
6  
7

8  
9  
10 13. Giri SN, Leonard S, Shi X, al. Effects of pirfenidone on the generation of  
11  
12 reactive oxygen species in vitro. *J Environ Pathol Toxicol Oncol* 1999; 18: 169-  
13  
14 177  
15

16  
17  
18 14. Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J et al. The  
19  
20 multifaceted role of pirfenidone and its novel targets. *Fibrogenesis and Tissue*  
21  
22 *Repair* 2010; 3: 16  
23

24  
25  
26  
27 15. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF  
28  
29 isoforms in bleomycin hamster model of lung fibrosis at the translational level.  
30  
31 *Am J Physiol Lung Cell Mol Physiol* 1999; 276: L311–L318.  
32  
33

34  
35  
36 16. Nakazato H, Oku H, Yamane S et al. A novel antifibrotic agent pirfenidone  
37  
38 suppresses tumor necrosis factor- $\alpha$  at the translational level. *Eur J Pharmacol*  
39  
40 2002; 446: 177-185  
41  
42

43  
44  
45 17. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and  
46  
47 prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-  
48  
49 induced murine pulmonary fibrosis. *Eur J Pharmacol* 2008; 590: 400–408.  
50  
51

52  
53 18. Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor  
54  
55 necrosis factor-a, enhances interleukin-10 and protects mice from endotoxic  
56  
57 shock. *Eur J Pharmacol* 2002; 446: 167–176.  
58  
59  
60

1  
2  
3 19. Tian XL, Yao W, Guo ZJ e al. Low dose pirfenidone suppresses  
4 transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1,  
5 and protects rats from lung fibrosis induced by bleomycin. Chin Med Sci J 2006;  
6 21: 145-151  
7  
8  
9

10  
11  
12  
13  
14 20. Ozes ON, Blatt LM. Development of a high throughput collagen assay using  
15 a cellular model of idiopathic pulmonary fibrosis. Chest 2006; 130: 230S  
16  
17  
18

19  
20  
21 21. Nayayama S, Mukae H, Sakamoto M et al. Pirfenidone inhibits the  
22 expression of HSP47 in TGF- $\beta$ 1-stimulated human lung fibroblasts. Life Sci  
23 2008; 82: 210-217.  
24  
25  
26

27  
28  
29 22. Hisatomi K, Mukae H, Sakamoto N. Pirfenidone inhibits TGF- $\beta$ -1 induced  
30 overexpression of collagen type I and heat shock protein 47 in A549 cells. BCM  
31 Pulm Med 2012, 12: 24  
32  
33  
34  
35

36  
37  
38 23. Jackson RM, Gomez Marin O. Development and utility of pirfenidone in the  
39 treatment of idiopathic pulmonary fibrosis: review of preclinical science and  
40 recent clinical trials. Trasplant Res Risk Manag 2011; 3:55-63.  
41  
42  
43  
44

45  
46  
47 24. Shi S, Wu J, Chen H et al. Single and multiple-dose pharmacokinetics of  
48 pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin  
49 Pharmacol 2007; 47: 1268-1276  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 25. Huang NY, Ding L, Wang J, et al. Pharmacokinetics, Safety and Tolerability  
4 of Pirfenidone and its Major Metabolite after Single and Multiple Oral Doses in  
5 Healthy Chinese Subjects under Fed Conditions. Drug Res (Sturg), 2013 Apr  
6 11.  
7  
8  
9  
10  
11  
12  
13  
14 26. Rubino CM, Bhavnani SM, Ambrose PG et al. Effect of food and antacids  
15 on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol  
16 ther 2009, 22: 279-285  
17  
18  
19  
20  
21  
22  
23 27. InterMune. Esbriet\_(pirfenidone): EU summary of product characteristics  
24 [online]. Available from URL:  
25 [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Pro](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Pro)  
26  
27  
28 duct\_Information/human/002154/WC500103049.pdf. (Last accessed 28 August  
29 2013).  
30  
31  
32  
33  
34  
35  
36 28. Taniyama M, Ohbayashi S, Narita M, et al. Pharmacokinetics of an  
37 antifibrotic agent, pirfenidone, in haemodialysis patients. Eur J Clin Pharmacol.  
38 1997; 52:77-8.  
39  
40  
41  
42  
43  
44  
45 29. Raghu G, Johnson CJ, Lockhart D et al. Treatment of idiopathic pulmonary  
46 fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir Crit Care Med  
47 1999; 159: 1061-1069  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 30. Azuma A, Nukiwa T, Tsuboi E et al. Double-blind, placebo controlled trial of  
4  
5 pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir. Crit Care  
6  
7 Med 2005; 171: 1040-1047  
8  
9

10  
11 31. Taniguchi H, Ebina M, Kondoh Y et al. Pirfenidone in idiopathic pulmonary  
12  
13 fibrosis. Eur Respir J 2010; 35: 821-829  
14  
15

16 \*\* Pivotal phase III clinical trial of pirfenidone in IPF  
17  
18  
19

20  
21 32. Azuma A, Tanaguchi Y, Ogura T et al. Exploratory analysis of a phase III  
22  
23 trial of pirfenidone identifies a subpopulation of patients with idiopathic  
24  
25 pulmonary fibrosis as benefiting from treatment. Respir Res 2011; 12: 143.  
26  
27

28  
29 33. Taniguchi H, Kondo H, Ebina M et al. The clinical significance of 5% change  
30  
31 in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis  
32  
33 of the pirfenidone trial. Respir Res 2011; 12: 93  
34  
35

36  
37 34. Noble PW, Albera C, Bradford WZ et al. Pirfenidone in patients with  
38  
39 idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;  
40  
41 377: 1760-1769  
42  
43

44  
45 \*\* The most outstanding phase III clinical trials of pirfenidone in IPF  
46  
47  
48

49 35. Richeldi L, du Bois RM. Pirfenidone in idiopathic pulmonary fibrosis: the  
50  
51 CAPACITY program. Expert Rev Respir Med 2011; 5:473-481  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 36. Spagnolo P, Del Giovane C, Luppi F et al. Non-steroid agents for idiopathic  
4 pulmonary fibrosis. Cochrane Database Syst Rev 2010;9:CD003134

5  
6  
7 \*\* Excellent review on the effects of non-steroid drugs in IPF  
8  
9

10  
11 37. Costabel U, Albera C, Bradford W et al. Analysis of lung function and survival  
12 in RECAP: an open-label extension study of pirfenidone in patients with  
13 idiopathic pulmonary fibrosis. Eur Respir J 2012; 40, Supl 56: 511s  
14  
15  
16  
17

18  
19  
20 38. Okuda R, Hagiwara E, Baba T et al. Safety and efficacy of pirfenidone in  
21 idiopathic pulmonary fibrosis in clinical practice. Resp. Med 2013; 107: 1431-  
22 1437  
23  
24  
25  
26  
27

28  
29 39. Bonella F, Wessendorf TE, Costabel U. Clinical experience with pirfenidone  
30 for the treatment of idiopathic pulmonary fibrosis. Dtsch Med Wochenschr 2013;  
31 138: 518-523  
32  
33  
34  
35  
36

37  
38 40. Iwasawa T, Ogura T, Sakai F et al. CT analysis of the effect of pirfenidone  
39 in patients with idiopathic pulmonary fibrosis. Eur J Radiol 2012; Mar 30 (Epub  
40 ahead of print).  
41  
42  
43  
44

45  
46 41. Jiang CH, Huang H, Liu J et al. Adverse events of pirfenidone for the  
47 treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials.  
48 PLoS One 7(10): e47024.  
49  
50  
51  
52

53  
54 \*\* Updated review on pirfenidone's adverse effects  
55  
56  
57  
58  
59  
60

1  
2  
3 42. Gahl WA, Brantly M, Troendle J et al. Effect of pirfenidone on the pulmonary  
4  
5 fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 2002; 76: 234-242.  
6  
7

8  
9  
10 43. O'Brien K, Troendle J, Gochuico BR et al. Pirfenidone for the treatment of  
11  
12 Hermansky-Pudlak syndrome pulmonary fibrosis. Mol Genet Metab 2011: 103:  
13  
14 128-134.  
15

16  
17  
18 44. InPharm. First idiopathic pulmonary fibrosis drug approved (on line).  
19  
20 Available from URL: [http://www.inpharm.com/news/149931/intermune-](http://www.inpharm.com/news/149931/intermune-idiopathic-pulmonary-fibrosis-esbriet-pirfenidone)  
21  
22 [idiopathic-pulmonary-fibrosis-esbriet-pirfenidone](http://www.inpharm.com/news/149931/intermune-idiopathic-pulmonary-fibrosis-esbriet-pirfenidone) (Last accessed 28 August  
23  
24 2013).  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Table 1.- Pirfenidone. Most commonly reported adverse reactions (> 10% patients)\*

Adverse event	Pirfenidone 2403 mg/ day	Placebo
Nausea	32.8**	13.3
Rash	28.7	8.6
Fatigue	22.3	13.3
Diarrhea	21.7	13.5
Dyspepsia	16.8	5.5
Photosensitivity	12.2	1.7

\* Data from clinical studies including 1345 healthy volunteers and patients (27).

\*\* % of patients

Table 2.- Potential drug interactions of pirfenidone

## CYP1A2 inhibitors

Fluvoxamine

Ciprofloxacin

Propafenone

Grapefruit juice

## CYP2C9 inhibitors

Amiodarone

Fluconazole

Voriconazole

## CYP2C19 inhibitors

Chloramphenicol

## CYP2D6 inhibitors

Fluoxetine

Paroxetine

Quinidine

## CYP1A2 inducers

Tobacco smoke

Omeprazole

Abbreviations: CYP, Cytochrome

**ABBREVIATIONS**

DL <sub>co</sub>	single-breath diffusing capacity for carbon monoxide
FVC	Forced vital capacity
HRCT	High resolution CT scan
IPF	Idiopathic pulmonary fibrosis
VC	Vital capacity
6MWT	Six- minute walk test

Table 1.- Pirfenidone. Most commonly reported adverse reactions (> 10% patients)\*

Adverse event	Pirfenidone 2403 mg/ day	Placebo
Nausea	32.8**	13.3
Rash	28.7	8.6
Fatigue	22.3	13.3
Diarrhea	21.7	13.5
Dyspepsia	16.8	5.5
Photosensitivity	12.2	1.7

\* Data from clinical studies including 1345 healthy volunteers and patients (27).

\*\* % of patients

Table 2.- Potential drug interactions of pirfenidone

## CYP1A2 inhibitors

Fluvoxamine

Ciprofloxacin

Propafenone

Grapefruit juice

## CYP2C9 inhibitors

Amiodarone

Fluconazole

Voriconazole

## CYP2C19 inhibitors

Chloramphenicol

## CYP2D6 inhibitors

Fluoxetine

Paroxetine

Quinidine

## CYP1A2 inducers

Tobacco smoke

Omeprazole

Abbreviations: CYP, Cytochrome

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Declaration of interest:**

Author 1 declares that he has received funding for given lectures at educational events and/or for scientific advice and / or research from Intermune, Actelion and Boehringer Ingelheim in relation to the subject of the manuscript.

Author 2: Intermune.

Author 3: Intermune, Zambon, Boehringer Ingelheim.

For Peer Review Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**PIRFENIDONE FOR THE TREATMENT OF IDIOPATHIC PULMONARY  
FIBROSIS**

For Peer Review Only

1  
2  
3  
4  
5 Antoni Xaubet, MD, PhD (corresponding author)  
6

7 Servei de Pneumologia. Hospital Clínic. Barcelona. Universitat de Barcelona  
8  
9 Centro de Investigaciones Médicas en Red de Enfermedades Respiratorias  
10  
11 (CIBERES)  
12

13  
14 Servei de Pneumologia. Hospital Clínic. Villarroel 170. Barcelona 08036. Spain  
15

16 Phone 60044756  
17

18 FAX 34932275455  
19

20 e-mail: [axaubet@clinic.ub.es](mailto:axaubet@clinic.ub.es)  
21  
22

23  
24  
25 Anna Serrano Mollar, PhD  
26

27 Institut d'Investigacions Biomèdiques de Barcelona. Consejo Superior de  
28  
29 Investgaciones Científicas. Barcelona. Centro de Investigaciones Médicas en  
30  
31 Red de Enfermedades Respiratorias (CIBERES).  
32  
33

34  
35  
36 Julio Ancochea, MD, PhD  
37

38 Servicio de Neumología. Hospital Universitario de La Princesa. Madrid  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**ABSTRACT**

**Introduction.** Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and lethal fibrosing interstitial pneumonia. The median survival from the onset of the symptoms is 2.8-4.2 years and the 5-year survival rate is 20%. Its poor prognosis, combined with the scarcity of treatment options, provides a strong rationale for the development of novel therapeutic strategies. During the last decade there has been a huge rise in clinical trials with antifibrotic drugs, although only pirfenidone (**Esbriet**) has shown a beneficial effect.

**Areas covered.** This article reviews the medical literature on the effectiveness and safety of pirfenidone in IPF, by means of a PubMed search from 1995 to present, completed by some data on file from the manufacturer.

**Expert opinion.** Pirfenidone is the only antifibrotic drug approved for the treatment of IPF. Pirfenidone presents a meaningful clinical effect on reductions in the decrease in forced vital capacity (FVC), six minute walk test (6MWT) distance and mortality, and it improves the progression-free survival in IPF patients with mild-moderate disease. Pirfenidone is well tolerated, with the most common side-effects being gastrointestinal discomfort and photosensitivity. Pirfenidone has a favorable benefit-risk profile and represents a suitable treatment option for patients with mild-moderate IPF.

**Key words.** Antifibrotic drugs, Idiopathic Pulmonary Fibrosis, Pirfenidone

## 1. INTRODUCTION

IPF is a chronic, progressive, and lethal fibrosing interstitial pneumonia, limited to the lung and associated with the histopathological and/or radiological pattern of usual interstitial pneumonia (1). Although its etiology is unknown and the pathogenesis only partly understood, our current knowledge suggests that damage to the alveolar epithelium is probably an important early event followed by an aberrant healing response. The median age at diagnosis is 66 years, with a male predominance, and prevalence has been increasing in recent years. The incidence of IPF is estimated to be between 4.6 and 7.4 cases/100,000, and the prevalence is between 13 cases/100,000 for females and 20 cases/100,000 for males (1). IPF is characterized by a progressive decline in pulmonary function, which quickly leads to respiratory failure and death, although some patients may have episodes of acute respiratory worsening despite previous stability. With a median survival from the onset of the symptoms of 2.8-4.2 years and a 5-year survival rate approaching 20%, IPF is more lethal than many malignant diseases. The poor prognosis, combined with the scarcity of treatment options, provides a strong rationale for the development of novel therapeutic strategies for this disease. During the last decade there has been a huge rise in clinical trials with antifibrotic drugs. In phase III randomized clinical trials with interferon gamma 1-b, pirfenidone, macitentan, bosentan, ambrisentan, warfarin, triple therapy (n-acetylcysteine, glucocorticoids, azathioprine), etanercept and sildenafil, only pirfenidone (**Esbriet**) has shown any beneficial effects in patients with IPF (2-4). Several national guidelines on IPF diagnosis and treatment from Spain, Germany, Denmark, Sweden, Austria, and Ireland, have recently recommended pirfenidone as first-choice therapeutic agent in IPF patients with

1  
2  
3 mild-moderate disease, defined as FVC predicted > 50% (5-9). In some other  
4  
5 European countries, such as Italy, pirfenidone is however, already commercially  
6  
7 available. The National Institute for Health and Clinical Excellence (NICE)  
8  
9 recommends pirfenidone as a therapeutic option in IPF patients with FVC  
10  
11 predicted between 50 and 80% (10).  
12

## 13 14 15 16 **2. OVERVIEW OF THE MARKET**

17  
18 Pirfenidone is the only pharmacological agent approved for the treatment of  
19  
20 mild-moderate IPF (11). Nowadays, there is no drug available for the treatment  
21  
22 of patients with IPF in an advance stage.  
23  
24

## 25 26 27 **3. INTRODUCTION TO PIRFENIDONE**

28  
29 Studies performed in animal models of pulmonary fibrosis and in human  
30  
31 pulmonary cell-based assays have demonstrated that pirfenidone is a  
32  
33 pleiotropic molecule with antifibrotic, anti-inflammatory and antioxidant effects  
34  
35 (12). The antioxidant effect occurs through its ability to scavenge reactive  
36  
37 oxygen species *in vitro* (13). Studies in animal models of pulmonary fibrosis  
38  
39 have shown that pirfenidone attenuates a range of inflammatory and profibrotic  
40  
41 molecules while down-regulating histological markers of fibrosis and cellular  
42  
43 proliferation (14). Pirfenidone inhibits the expression of transforming growth  
44  
45 factor (TGF)- $\beta$  and the tissue inhibitor of metalloproteinase-1 (TIMP-1), and  
46  
47 blocks the proliferative effects of platelet-derived growth factor (PDGF).  
48  
49 Furthermore, pirfenidone inhibits the release of proinflammatory cytokines such  
50  
51 as, tumor necrosis factor (TNF)- $\alpha$ , interleukin (IL-1)- $\beta$ , IL-6, IL-8 and IL-12, as  
52  
53 well as increasing the expression of the anti-inflammatory cytokine IL-10,  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 attenuating the release of chemotactic cytokines and reducing the accumulation  
4  
5 of inflammatory cells in response to different stimuli (14-19).  
6

7  
8 In addition to the modulation of mediators in animal models, cell-based assays  
9  
10 have demonstrated that pirfenidone inhibits the expression of heat shock  
11  
12 protein (HSP) 47 in cultured normal lung fibroblasts stimulated with TGF- $\beta$ -1; it  
13  
14 was also able to inhibit the expression of collagen in fibroblasts isolated from  
15  
16 IPF patients (20, 21). Moreover, pirfenidone inhibits the overexpression of  
17  
18 collagen type I and HSP47 in the alveolar epithelial cell line (A549 cells) (22).  
19

### 20 21 22 23 **3.1 CHEMISTRY**

24  
25 Pirfenidone is an orally bioavailable synthetic molecule. Pirfenidone is a  
26  
27 heterocyclic pyridine (5-methyl-1-phenyl-2-[1H]-pyridine) with a molecular  
28  
29 weight of 185.22. Pyridines are derived from coal combustion, and can be  
30  
31 synthesized from aldehyde and ammonia. They are highly soluble in  
32  
33 dimethylsulfoxide, twice in water and chloroform, and in alcohol. In aqueous  
34  
35 solution the maximum possible concentration is 2% (23).  
36  
37  
38  
39

### 40 41 42 **3.2 PHARMACOKINETICS AND METABOLISM**

43  
44 Oral pirfenidone has linear pharmacokinetics over the dose range of 200-600  
45  
46 mg. (24). After a single dose of pirfenidone with food at the recommended  
47  
48 maintenance dose of 801 mg, the mean maximum plasma concentration ( $C_{max}$ )  
49  
50 is 7.9 mg/L in healthy adults. Absorption occurs quickly, the time to maximum  
51  
52 ( $T_{max}$ ) values being achieved in 30-60 min (25). Median time to  $C_{max}$  is 3.5 h.  
53  
54 However, the  $C_{max}$  is significantly lower when the drug is administered in the fed  
55  
56 versus fasting states (26). Concomitant intake of food reduce by 20% the rate  
57  
58  
59  
60

1  
2  
3 and extent of absorption, which is associated with a better tolerability to  
4  
5 pirfenidone. ~~It has been shown that healthy volunteers who received pirfenidone~~  
6  
7 ~~with food had~~ and a lower incidence of gastrointestinal adverse events, ~~than~~  
8  
9 ~~those who received pirfenidone without food.~~ (24). In clinical trials, at  
10  
11 concentrations of 1-1000 mg/L, 50-58% of pirfenidone bound to plasma  
12  
13 proteins, predominantly albumin (27). Pirfenidone is predominantly metabolized  
14  
15 by the cytochrome (CYP) P450 CYP1A2 enzyme, although other CYP  
16  
17 enzymes, including CYP2C9, 2C19, 2D6, and 2E, also contribute to the  
18  
19 metabolism. The major metabolite of pirfenidone is 5-carboxy-pirfenidone which  
20  
21 is inactive. After a single 801 mg dose, the terminal elimination half-life was 2.9  
22  
23 h (without food) and 2.4 h (with food). No significant gender differences were  
24  
25 noted for the pharmacokinetic variables (26). Eighty percent of the administered  
26  
27 dose was excreted in the urine primarily as 5-carboxy-pirfenidone and less than  
28  
29 1% of the dose recovered in the urine was unaltered, after 6 h of administration.  
30  
31  
32  
33  
34 Pirfenidone bioavailability is increased by a mean of 60% in patients with  
35  
36 moderate hepatic function impairment. No clinical relevant changes have been  
37  
38 observed in pharmacokinetics in patients with mild to severe renal function  
39  
40 impairment. However, the drug is contraindicated in patients with severe renal  
41  
42 impairment (creatinine clearance of < 30 mL/min) or end stage renal disease  
43  
44 requiring dialysis (28).

45  
46  
47 Pirfenidone may interact with drugs that inhibit CYP1A2, particularly  
48  
49 fluvoxamine, ciprofloxacin, and propafenone. Consumption of grapefruit also  
50  
51 inhibits CYP1A2. Concomitant treatment with inhibitors of other CYP  
52  
53 isoenzymes involved in the metabolism of pirfenidone (fluconazole,  
54  
55 chloramfenicol, fluoxetine, paroxetine, amiodarone) may interact with  
56  
57  
58  
59  
60

1  
2  
3 pirfenidone. Pirfenidone can also interact with CYP1A2, inducers, such as  
4  
5 tobacco smoke and omeprazole (27) (Table 1).  
6  
7

#### 9 10 **4. CLINICAL EFFICACY**

##### 11 **4.1 Clinical trials**

12  
13  
14 In a prospective, open-label phase II study, pirfenidone was evaluated for its  
15  
16 tolerability and usefulness in patients with advanced IPF, progressive disease  
17  
18 and lack of response to conventional therapy (prednisone with or without  
19  
20 immunosuppressives). Fifty-four patients were followed for mortality, changes in  
21  
22 lung function and adverse effects. Patients whose lung function had  
23  
24 deteriorated before enrolment appeared to stabilize after beginning the  
25  
26 treatment. Patients with higher single-breath diffusing capacity for carbon  
27  
28 monoxide ( $DL_{CO}$ ) (> 30% predicted) at entry had longer survival rates. The  
29  
30 adverse effects were minor (29).  
31  
32

33  
34 The first large-scale trial of pirfenidone was a Japanese multicenter randomized  
35  
36 placebo-controlled phase II study of 107 subjects who received either  
37  
38 pirfenidone 600 mg three times daily (n = 72) or placebo (n = 35). The trial was  
39  
40 designed to run for 1 year. Although there was a significant decrease in the  
41  
42 decline of FVC in the pirfenidone group, 9-month interim results showed that  
43  
44 five subjects from the placebo group had suffered acute exacerbation of the  
45  
46 disease compared to none in the pirfenidone group, and the study was halted  
47  
48 (30).  
49

50  
51 A phase III clinical trial conducted over 52 weeks was also developed in Japan.  
52  
53 A total of 275 patients were randomized to either high-dose (1800 mg/day) or  
54  
55 low-dose (1200 mg/day) pirfenidone or placebo at the ratio of 2:1:2. Significant  
56  
57  
58  
59  
60

1  
2  
3 differences were observed in vital capacity (VC) decline (primary end-point)  
4  
5 between the placebo group and the high-dose group and improved progression-  
6  
7 free survival time was seen in the high-dose group. (31). In order to find out  
8  
9 which patients specifically benefit from pirfenidone, an additional exploratory  
10  
11 analysis was performed with the data of this trial. Significant efficacy of  
12  
13 pirfenidone in reducing the decline in VC was seen in a subpopulation with  
14  
15 %VC  $\geq$  70% and oxygen saturation at baseline (SpO<sub>2</sub>) < 90%. These are  
16  
17 mutually conflicting characteristics. According to the author's opinion, the  
18  
19 desaturation exhibited by the subgroup with the better-preserved lung function  
20  
21 may have been due to the development of fibrosis with inflammatory edema  
22  
23 and not to established fibrosis. In this subpopulation, pirfenidone also  
24  
25 suppressed cough and dyspnea (32). Recently, marginal decline in FVC (5%)  
26  
27 has been reported as being associated with poor outcome in IPF. In the same  
28  
29 clinical trial, Taniguchi et al. sought to evaluate the efficacy of pirfenidone from  
30  
31 the aspects of 5% changes in VC. When 5% change in VC was used as an  
32  
33 index instead of the 10% change, the efficacy of pirfenidone could be evaluated  
34  
35 with higher sensitivity over the 12 months study (33).  
36  
37  
38  
39

40  
41 The CAPACITY phase III trials consisted of two concurrent multinational  
42  
43 randomized double-blind placebo-controlled phase III trials (004 and 006)  
44  
45 conducted over 72 weeks and designed to evaluate the safety and efficacy of  
46  
47 pirfenidone in patients with mild-moderate disease (34, 35). In trial 004, 174  
48  
49 patients were assigned to high-dose pirfenidone (2403 mg/day), 87 to low dose  
50  
51 (1197 mg/day) and 174 to placebo. In study 006, 171 patients were assigned to  
52  
53 high-dose pirfenidone (2403 mg/day), and 173 to placebo. In study 004, the  
54  
55 higher dose of pirfenidone met the primary endpoint, decreasing the decline in  
56  
57  
58  
59  
60

1  
2  
3 FVC. In contrast, trial 006 failed to show a significant reduction in FVC, although  
4  
5 there was a reduced decline in distance walked in the 6MWT (secondary end-  
6  
7 point). The differences observed between the two studies in the effect of  
8  
9 pirfenidone may be explained by the fact that the subjects in the 006 placebo  
10  
11 group had a slower rate of decline compared to those in 004. When 004 and  
12  
13 006 study data were pooled, pirfenidone showed meaningful clinical effects on  
14  
15 FVC % predicted (decrease in the decline by 30%), progression free survival  
16  
17 and 6MWT distance at the dose of 2403 mg/day. Although these trials were not  
18  
19 empowered to detect an effect on mortality, IPF-related mortality was reduced  
20  
21 by 28%. A Cochrane review encompassing the two Japanese trials and the  
22  
23 CAPACITY studies, has demonstrated that pirfenidone improves progression-  
24  
25 free survival by 30%. (36). However, there are still no data for having longer  
26  
27 overall survival in patients treated with pirfenidone.  
28  
29  
30

31  
32 The RECAP study is an ongoing open-label extension study evaluating the  
33  
34 long-term administration of pirfenidone in patients who completed phase III  
35  
36 CAPACITY program. Preliminary results in 178 patients show that FVC and  
37  
38 survival outcomes in patients newly treated with pirfenidone in the RECAP  
39  
40 study were similar to those treated in the CAPACITY trials. These data provide  
41  
42 further evidence to support the beneficial effect of pirfenidone in IPF (37). A  
43  
44 phase III study comparing pirfenidone with placebo in patients with mild-to-  
45  
46 moderate IPF is currently underway in the US (ASCEND trial, NCT01366299).  
47  
48 The PANORAMA study (A Randomized, Double-Blind, Placebo-Controlled,  
49  
50 Phase II Study of the Safety and Tolerability of *N*-Acetylcysteine in Patients  
51  
52 with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone,  
53  
54 EUDRACT 2012-000564-14) is also ongoing. The objective of this trial is to  
55  
56  
57  
58  
59  
60



1  
2  
3 assess the safety and tolerability of the treatment with N–Acetylcysteine in  
4  
5 patients with mild-to-moderate IPF on background treatment of pirfenidone.  
6  
7  
8

#### 9 10 **4.2 Posology and method of administration**

11 Pirfenidone is indicated in adults for the treatment of mild-to-moderate IPF (FVC  
12 > 50% predicted (5-9). The National Institute for Health and Clinical Excellence  
13 recommends pirfenidone in patients with FVC between 50% and 80% predicted  
14 (10). The approved dose is 2403 mg/day. Each capsule contains 267 mg. Upon  
15 initiating treatment, the dose should be titrated to the recommended daily dose  
16 over a 14-day period: days 1 to 7, one capsule three times a day (801 mg/day);  
17 days 8 to 14, two capsules, three times a day (1602 mg/day) and day 15  
18 onward, three capsules, three times a day (2403 mg/day). The drug should be  
19 taken with food to reduce the possibility of gastrointestinal adverse events and  
20 dizziness (27). The recommended treatment duration is at least 12 months. If  
21 there is improvement or stabilization of the disease, the treatment should be  
22 continued. In case of deterioration, the advisability of continuing treatment or  
23 instigating other therapeutic strategies should be considered for each patient.  
24  
25 ~~However, it~~ It is recommended that treatment should be discontinued if there is  
26 evidence of disease progression, that is, a decline in percentage predicted FVC  
27 of 10% or more within any 12 month period (5, 10). ~~However, the decision of~~  
28 ~~discontinuation should be considered according to the individual benefit and~~  
29 ~~adverse effects under the comprehensive evaluation.~~  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### 4.3 Post marketing studies

Open-label studies have been developed, to confirm the efficacy, safety and tolerability of pirfenidone and to optimize its indications.

A European Named Patient Program (NPP) was established by Intermune to make pirfenidone accessible to patients with IPF during the period between the authorization of the drug and its availability upon prescription. The results of this program have not yet been published. The PASSPORT study (Post-Authorisation Safety Study of **Esbriet®** (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting) is also ongoing; its objective is to evaluate the long-term safety of pirfenidone.

In a retrospective study, Okuda et al. (38) have described the effects of pirfenidone, at the dose of 1800 mg/day during 6 months, in 76 patients with mild-to-severe IPF. Pirfenidone tended to attenuate the degree of decline in FVC, particularly in the subgroup of patients with FVC < 60% and showed greater efficacy in patients with a decline in FVC > 150 ml during the 6-months period before the start of therapy. Thus, the degree of disease progression prior to the initiation of therapy had an impact on the response to pirfenidone. The most frequent adverse effects were anorexia (42%), increase in gamma glutamyl transpeptidase (22%), fatigue (14%) and photosensitivity (18%). All the reported adverse effects were, however, mild, reversible and left no sequelae. Moreover, Bonella et al. (39), have reported data on the safety and efficacy of pirfenidone (2403 mg/ day) in 45 patients with mild-moderate IPF (mean duration of treatment 48 weeks). Sixteen patients (35%) received pirfenidone as monotherapy and 29 (65%) in combination with corticosteroids and /or N-acetylcysteine. The course of the disease was stable during treatment with

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

pirfenidone in two out of every three patients. Twenty-six patients (58%) suffered from side effects, mostly gastrointestinal, but pirfenidone was discontinued because of side effects in only six patients. The results of this study confirm the efficacy and safety of pirfenidone in the treatment of IPF. In another study, Inoue et al. have reported the efficacy and safety profile of pirfenidone in more than 1,300 Japanese patients with IPF. Pirfenidone kept the decline in VC to a minimum (mean change – 0.07 L) in patients treated 6 months or longer. Incidences of decreased appetite, photosensitivity reaction and nausea were 29%, 15% and 8.3% respectively, although most of these adverse drug reactions were manageable (40).

Iwasawa et al. (41) investigated the usefulness of high resolution CT scan (HRCT) in the imaging assessment of the response to pirfenidone therapy. Seventy-eight patients (38 treated with pirfenidone and 40 matched controls) were given HRCT on two occasions, with a one-year interval in between. A significantly larger proportion of patients treated with pirfenidone showed more stable pulmonary function parameters than the controls (65.6% vs 37.5%). The decline in VC correlated with the increase in fibrotic lesions in CT scan. These results suggest that CT scan may be useful for evaluating the pirfenidone-induced slowing progression of pulmonary fibrosis.

## 5. SAFETY AND TOLERABILITY

Jiang et al (42) have reported the results of a meta-analysis to analyze the safety profile of pirfenidone for treating pulmonary fibrosis. Six-randomized controlled trials were analyzed. A total of 1073 patients were enrolled, 561 in the pirfenidone group, and 512 in the placebo group. Four trials assessed the

1  
2  
3 treatment of IPF and the remaining two studies, assessed the treatment of  
4  
5 Hermansky–Pudlak syndrome (30, 31, 34, 43, 44). The combined results of the  
6  
7 six trials revealed that the pirfenidone group had a significantly higher rate of  
8  
9 gastrointestinal, neurological and dermatological adverse events. However,  
10  
11 adverse effects were generally mild or moderate in severity and without any  
12  
13 clinically significant consequences. Most of the adverse effects disappeared  
14  
15 with a decrease in the dose or temporary discontinuation of medication.  
16  
17

18  
19 The most commonly reported ( $\geq 10\%$ ) adverse reactions during treatment with  
20  
21 pirfenidone at a dose of 2403 mg/day are nausea, rash, fatigue, diarrhea,  
22  
23 dyspepsia and photosensitivity reaction (table 2). Less frequent adverse effects  
24  
25 are anorexia, insomnia, hot flush and alteration in the hepatic enzymes alanin  
26  
27 and aspartate aminotransferases, and gamma glutamyl transferase (27).  
28

29  
30 Gastrointestinal events are less frequent if the drug is administered with food.  
31  
32 Patients with photosensitivity reaction or rash should use protective sun  
33  
34 creams, wear clothing that protects against sun exposure and avoid direct  
35  
36 sunlight. In case of adverse events, the dose of pirfenidone should be adjusted  
37  
38 or the treatment discontinued, according to the established recommendations.  
39

40  
41 There are no data on the use of pirfenidone during pregnancy (27).  
42

43  
44 Pirfenidone is contraindicated in case of hypersensitivity to the drug or to any of  
45  
46 its excipients, concomitant use of fluvoxamine, severe hepatic impairment or  
47  
48 end-stage liver disease or severe renal impairment or end-stage renal disease  
49  
50 requiring dialysis. Pirfenidone should be used with caution in patients treated  
51  
52 with inhibitors or inducers of CYP1A2 (table 1) (27).  
53  
54  
55  
56  
57  
58  
59  
60

## 6. REGULATORY AFFAIRS

Pirfenidone is an orally administered pyridine that was granted orphan drug approval in the European Union for the treatment of mild-to-moderate IPF in 2011 and it is the only pharmacological agent available for this indication (45). In Europe, it is marketed ~~under the brand name Esbriet<sup>®</sup>~~ by Intermune Inc. In Japan, pirfenidone has been approved for marketing since 2008 ~~under the brand name Pirespa<sup>®</sup>~~ by Shionogi & Co. In 2010, the Food and Drug Administration (FDA) denied approval for pirfenidone. A new drug application to the FDA is expected depending on the results of the ongoing phase III trial ASCEND (Efficacy and safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis).

## 7. CONCLUSION

IPF is a chronic, progressive, and lethal fibrosing interstitial pneumonia. Its poor prognosis, combined with the scarcity of treatment options, provides a strong rationale for the development of novel therapeutic strategies for this disease. During the last decade several clinical trials with antifibrotic drugs have been developed, although only pirfenidone has shown a beneficial effect. Recent national guidelines and the National Institute for Health and Clinical Excellence recommend pirfenidone as first-choice therapeutic agent in IPF patients with mild-moderate disease, defined as FVC > 50% of predicted. Pirfenidone's adverse-effect profile is acceptable in a disease as severe as IPF. Nowadays, pirfenidone is the only pharmacological agent approved for the treatment of mild-moderate IPF.

## 8. EXPERT OPINION

IPF is a rare and orphan disease characterized by a progressive lung fibrosis with a median survival from the onset of the symptoms of 2.8 to 4.2 years. An international consensus statement for the diagnosis and treatment of IPF was published in 2011. In this consensus, the diagnostic criteria of IPF were redefined and new decisions for diagnosis and clinical management were established. However, the committee did not find sufficient evidence to support the use of any specific pharmacologic therapy for patients with IPF. Since the publication of the 2011 international consensus we have known the final results of several clinical trials with antifibrotic drugs, although only pirfenidone has shown any beneficial effect. Four key clinical trials have endorsed the efficacy and tolerability of pirfenidone. Pirfenidone has shown clinically meaningful effects on decreases in the decline of % FVC, 6MWT distance and IPF-related mortality, as well as on improvements in progression-free survival. In addition, pirfenidone could prevent symptoms related to disease progression, decrease dependency on oxygen, and reduce hospitalizations. Moreover, post-marketing studies have confirmed these beneficial effects of pirfenidone. Thus, pirfenidone seems to have a modest but measurable effect on slowing the progression of the disease, but there is uncertainty in whether this benefit will persist over time. Therefore, the main goal of long term treatment with pirfenidone is to increase the survival. It is an important point because there are still no data for having longer overall survival of patients treated with pirfenidone. In this context, open-label and placebo-controlled studies are underway to confirm the efficacy and safety of pirfenidone. Pirfenidone is well tolerated, with the most common side-effects being gastrointestinal discomfort and photosensitivity. It is


1  
2  
3 considered that the pirfenidone's adverse-effect profile is acceptable in a  
4  
5 disease as severe as IPF.  
6


7 Pirfenidone is the only pharmacological agent approved for the treatment of  
8  
9 mild-moderate IPF. Recent national guidelines and the National Institute for  
10  
11 Health and Clinical Excellence recommend pirfenidone as first-choice  
12  
13 therapeutic agent in IPF patients with mild-moderate disease, defined as FVC >  
14  
15 50% of predicted. Depending on the results of the ongoing clinical trials,  
16  
17 pirfenidone will likely become in the next few years in the main treatment for  
18  
19 mild- moderate IPF.  
20  
21  
22

23 Nowadays, there is no drug available for the treatment of patients with IPF with  
24  
25 advanced disease, which is defined by FVC lower than 50% predicted. To date,  
26  
27 the majority of clinical trials in IPF have included only patients with mild-  
28  
29 moderate disease. One of the research projects that should be done, is a  
30  
31 clinical trial of pirfenidone in IPF patients with advanced disease, with the aim of  
32  
33 evaluating its efficacy in this group of patients.  
34  
35

36 At present, clinical trials are underway with other antifibrotic mediators in  
37  
38 patients with IPF, but we still do not know the results. In conclusion, pirfenidone  
39  
40 has a favourable benefit-risk profile and represents a suitable treatment option  
41  
42 for IPF.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**9. DRUG SUMMARY BOX**

Drug name	Pirfenidone
Phase	Marketed
Indication	mild-moderate idiopathic pulmonary fibrosis
Pharmacology description	antifibrotic, anti-inflammatory, antioxidant
Route of administration	oral
Chemical structure	



Pivotal trials (30, 31, 34)



**REFERENCES**

1. Raghu G, Collard HR, Egan JJ et al. An official ATS/ERS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med* 2011; 183: 788-824.
2. Luppi F, Spagnolo P, Cerri S et al. The big clinical trials in idiopathic pulmonary fibrosis. *Curr Opin Pulm Med* 2012; 18: 428-432.
3. Raghu G, Behr J, Brown KK et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel randomised trial. *Ann Intern Med* 2013; 158: 641-649.
4. Raghu G, Million-Rousseau R, Morganti A et al. Macitentan for the treatment of IPF: the randomized controlled MUSIC trial. *Eur Respir J* 2013; May 16 (Epub ahead of print).
5. Xaubet A, Ancochea J, Bollo E et al. Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. *Arch Bronconeumol* 2013; 49: 343-353.
6. Behr J, Günther A, Ammenwerth W et al. German Guideline for Diagnosis and Management of idiopathic Pulmonary Fibrosis. *Pneumologie* 2013; 67:81-111.

- 1  
2  
3  
4  
5 7. Idiopathic pulmonary fibrosis guidelines. Danish Society of Respiratory  
6  
7 Medicine [www.lungemedicin.dk](http://www.lungemedicin.dk) (Last accessed 29 August 2013).  
8  
9  
10  
11  
12 8. Position Statement from the Irish Thoracic Society on the treatment of  
13  
14 idiopathic pulmonary fibrosis:  
15  
16 [http://www.irishthoracicsociety.com/images/uploads/ITS%20Statement%](http://www.irishthoracicsociety.com/images/uploads/ITS%20Statement%20Final.pdf)  
17  
18 [20Final.pdf](http://www.irishthoracicsociety.com/images/uploads/ITS%20Statement%20Final.pdf) (Last accessed 28 August 2013).  
19  
20  
21  
22  
23 9. Care programs for idiopathic pulmonary fibrosis. Swedish Society for  
24  
25 Pulmonary Medicine: [http://www.slmf.se/sites/default/files/VPIL\\_](http://www.slmf.se/sites/default/files/VPIL_) (Last  
26  
27 [accessed 28 August 2013](http://www.slmf.se/sites/default/files/VPIL_)  
28  
29  
30  
31  
32 10. Pirfenidone for treating idiopathic pulmonary fibrosis. National Institute for  
33  
34 Health and Clinical Excellence:  
35  
36 <http://guidance.nice.org.uk/TA/Wave23/25/FAD/FinalAppraisalDetermination/pdf/English>. (Last accessed 28 August 2013).  
37  
38  
39  
40  
41  
42  
43 11. Potts J, Yogaratnam D. Pirfenidone: a novel agent for the treatment of  
44  
45 idiopathic pulmonary fibrosis. *Ann Pharmacother* 2013; 47: 361-367.  
46  
47 \*A practical and concise recent review on pirfenidone  
48  
49  
50  
51  
52 12. Schaefer CJ, Ruhrmund DW, Pan L et al. Antifibrotic activities of  
53  
54 pirfenidone in animal models. *Eur Respir Rev* 2011;20:120,85-97.  
55  
56  
57  
58  
59  
60

1  
2  
3 \*Updated review on the antifibrotic effects of pirfenidone in animal  
4 models of pulmonary fibrosis.  
5  
6  
7  
8

9  
10 13.Giri SN, Leonard S, Shi X, al. Effects of pirfenidone on the generation of  
11 reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol 1999;  
12 18: 169-177.  
13  
14

15  
16  
17  
18 14.Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J et al. The  
19 multifaceted role of pirfenidone and its novel targets. Fibrogenesis and  
20 Tissue Repair 2010; 3: 16.  
21  
22  
23

24  
25  
26  
27 15.Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF  
28 isoforms in bleomycin hamster model of lung fibrosis at the translational  
29 level. Am J Physiol Lung Cell Mol Physiol 1999; 276: L311–L318.  
30  
31  
32  
33

34  
35  
36 16.Nakazato H, Oku H, Yamane S et al. A novel antifibrotic agent  
37 pirfenidone suppresses tumor necrosis factor- $\alpha$  at the translational level.  
38 Eur J Pharmacol 2002; 446: 177-185.  
39  
40  
41  
42

43  
44  
45 17.Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone  
46 and prednisolone: different effects on pulmonary cytokines and growth  
47 factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol  
48 2008; 590: 400–408.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 18. Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor  
4 necrosis factor- $\alpha$ , enhances interleukin-10 and protects mice from  
5 endotoxic shock. *Eur J Pharmacol* 2002; 446: 167–176.  
6  
7  
8  
9  
10  
11 19. Tian XL, Yao W, Guo ZJ et al. Low dose pirfenidone suppresses  
12 transforming growth factor beta-1 and tissue inhibitor of  
13 metalloproteinase-1, and protects rats from lung fibrosis induced by  
14 bleomycin. *Chin Med Sci J* 2006; 21: 145-151.  
15  
16  
17  
18  
19  
20  
21  
22 20. Ozes ON, Blatt LM. Development of a high throughput collagen assay  
23 using a cellular model of idiopathic pulmonary fibrosis. *Chest* 2006; 130:  
24 230S.  
25  
26  
27  
28  
29  
30  
31 21. Nayayama S, Mukae H, Sakamoto M et al. Pirfenidone inhibits the  
32 expression of HSP47 in TGF- $\beta$ 1-stimulated human lung fibroblasts. *Life*  
33 *Sci* 2008; 82: 210-217.  
34  
35  
36  
37  
38  
39  
40 22. Hisatomi K, Mukae H, Sakamoto N. Pirfenidone inhibits TGF- $\beta$ 1 induced  
41 overexpression of collagen type I and heat shock protein 47 in A549  
42 cells. *BCM Pulm Med* 2012, 12: 24.  
43  
44  
45  
46  
47  
48  
49 23. Jackson RM, Gomez Marin O. Development and utility of pirfenidone in  
50 the treatment of idiopathic pulmonary fibrosis: review of preclinical  
51 science and recent clinical trials. *Trasplant Res Risk Manag* 2011; 3:55-  
52 63.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5 24. Shi S, Wu J, Chen H et al. Single and multiple-dose pharmacokinetics of  
6  
7       pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin  
8  
9       Pharmacol 2007; 47: 1268-1276.  
10  
11  
12  
13  
14 25. Huang NY, Ding L, Wang J, et al. Pharmacokinetics, Safety and  
15  
16       Tolerability of Pirfenidone and its Major Metabolite after Single and  
17  
18       Multiple Oral Doses in Healthy Chinese Subjects under Fed Conditions.  
19  
20       Drug Res (Sturg), 2013 Apr 11.  
21  
22  
23  
24  
25 26. Rubino CM, Bhavnani SM, Ambrose PG et al. Effect of food and  
26  
27       antiacids on the pharmacokinetics of pirfenidone in older healthy adults.  
28  
29       Pulm Pharmacol ther 2009, 22: 279-285.  
30  
31  
32  
33  
34 27. InterMune. Esbriet\_(pirfenidone): EU summary of product characteristics  
35  
36       [online]. Available from URL:  
37  
38       [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR - Pro](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Pro)  
39  
40       [duct\\_Information/human/002154/WC500103049.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002154/WC500103049.pdf). (Last accessed 28  
41  
42       August 2013).  
43  
44  
45  
46  
47 28. Taniyama M, Ohbayashi S, Narita M, et al. Pharmacokinetics of an  
48  
49       antifibrotic agent, pirfenidone, in haemodialysis patients. Eur J Clin  
50  
51       Pharmacol. 1997; 52:77-8.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 29. Raghu G, Johnson CJ, Lockhart D et al. Treatment of idiopathic  
4 pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir  
5 Crit Care Med 1999; 159: 1061-1069.  
6  
7

8  
9  
10  
11 30. Azuma A, Nukiwa T, Tsuboi E et al. Double-blind, placebo controlled trial  
12 of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir.  
13 Crit Care Med 2005; 171: 1040-1047.  
14  
15  
16

17  
18  
19  
20 31. Taniguchi H, Ebina M, Kondoh Y et al. Pirfenidone in idiopathic  
21 pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.  
22  
23

24 \*\* Pivotal phase III clinical trial of pirfenidone in IPF.  
25  
26  
27

28  
29 32. Azuma A, Tanaguchi Y, Ogura T et al. Exploratory analysis of a phase III  
30 trial of pirfenidone identifies a subpopulation of patients with idiopathic  
31 pulmonary fibrosis as benefiting from treatment. Respir Res 2011; 12:  
32 143.  
33  
34  
35  
36  
37

38  
39 33. Taniguchi H, Kondo H, Ebina M et al. The clinical significance of 5%  
40 change in vital capacity in patients with idiopathic pulmonary fibrosis:  
41 extended analysis of the pirfenidone trial. Respir Res 2011; 12: 93.  
42  
43  
44  
45  
46  
47

48  
49 34. Noble PW, Albera C, Bradford WZ et al. Pirfenidone in patients with  
50 idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet  
51 2011; 377: 1760-1769.  
52  
53  
54

55 \*\* The most outstanding phase III clinical trials of pirfenidone in IPF.  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 35. Richeldi L, du Bois RM. Pirfenidone in idiopathic pulmonary fibrosis: the  
6  
7 CAPACITY program. *Expert Rev Respir Med* 2011; 5:473-481.  
8  
9

10  
11 36. Spagnolo P, Del Giovane C, Luppi F et al. Non-steroid agents for  
12  
13 idiopathic pulmonary fibrosis. *Cochrane Database Syst Rev*  
14  
15 2010;9:CD003134.  
16  
17

18 \*\* Excellent review on the effects of non-steroid drugs in IPF.  
19  
20

21  
22 37. Costabel U, Albera C, Bradford W et al. Analysis of lung function and  
23  
24 survival in RECAP: an open-label extension study of pirfenidone in  
25  
26 patients with idiopathic pulmonary fibrosis. *Eur Respir J* 2012; 40, Supl  
27  
28 56: 511s.  
29  
30

31  
32 38. Okuda R, Hagiwara E, Baba T et al. Safety and efficacy of pirfenidone in  
33  
34 idiopathic pulmonary fibrosis in clinical practice. *Resp. Med* 2013; 107:  
35  
36 1431-1437.  
37  
38  
39

40  
41 39. Bonella F, Wessendorf TE, Costabel U. Clinical experience with  
42  
43 pirfenidone for the treatment of idiopathic pulmonary fibrosis. *Dtsch Med*  
44  
45 *Wochenschr* 2013; 138: 518-523.  
46  
47  
48

49  
50 40. Inoue Y, Azuma A, Ogura T et al. All-case post-marketing surveillance of  
51  
52 pirfenidone in Japan: clinical characteristics, efficacy and safety profile in  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 > 1300 patients with idiopathic pulmonary fibrosis. (IPF). European  
4 Respiratory Society Annual Congress 2013; Session 345.  
5  
6  
7

8  
9  
10 41. Iwasawa T, Ogura T, Sakai F et al. CT analysis of the effect of  
11 pirfenidone in patients with idiopathic pulmonary fibrosis. Eur J Radiol  
12 2012; Mar 30 (Epub ahead of print).  
13  
14

15  
16  
17  
18 42. Jiang CH, Huang H, Liu J et al. Adverse events of pirfenidone for the  
19 treatment of pulmonary fibrosis: a meta-analysis of randomized  
20 controlled trials. PLoS One 7(10): e47024.  
21  
22  
23

24 \*\* Updated review on pirfenidone's adverse effects.  
25  
26  
27

28  
29 43. Gahl WA, Brantly M, Troendle J et al. Effect of pirfenidone on the  
30 pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab  
31 2002; 76: 234-242.  
32  
33  
34

35  
36  
37  
38 44. O'Brien K, Troendle J, Gochuico BR et al. Pirfenidone for the treatment  
39 of Hermansky-Pudlak syndrome pulmonary fibrosis. Mol Genet Metab  
40 2011; 103: 128-134.  
41  
42  
43

44  
45  
46  
47 45. InPharm. First idiopathic pulmonary fibrosis drug approved (on line).  
48 Available from URL: [http://www.inpharm.com/news/149931/intermune-  
49 idiopathic-pulmonary-fibrosis-esbriet-pirfenidone](http://www.inpharm.com/news/149931/intermune-idiopathic-pulmonary-fibrosis-esbriet-pirfenidone) (Last accessed 28  
50 August 2013).  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Table 1.- Pirfenidone. Most commonly reported adverse reactions (> 10% patients)\*

Adverse event	Pirfenidone 2403 mg/ day	Placebo
Nausea	32.8**	13.3
Rash	28.7	8.6
Fatigue	22.3	13.3
Diarrhea	21.7	13.5
Dyspepsia	16.8	5.5
Photosensitivity	12.2	1.7

\* Data from clinical studies including 1,345 healthy volunteers and patients (27).

\*\* % of patients

Table 2.- Potential drug interactions of pirfenidone

## CYP1A2 inhibitors

Fluvoxamine

Ciprofloxacin

Propafenone

Grapefruit juice

## CYP2C9 inhibitors

Amiodarone

Fluconazole

Voriconazole

## CYP2C19 inhibitors

Chloramphenicol

## CYP2D6 inhibitors

Fluoxetine

Paroxetine

Quinidine

## CYP1A2 inducers

Tobacco smoke

Omeprazole

Abbreviations: CYP, Cytochrome

**ABBREVIATIONS**

DL <sub>co</sub>	single-breath diffusing capacity for carbon monoxide
FVC	Forced vital capacity
HRCT	High resolution CT scan
IPF	Idiopathic pulmonary fibrosis
VC	Vital capacity
6MWT	Six- minute walk test